Jay Bradner News Today

The monoclonal antibody Uplizna met key endpoints in a phase 3 trial for the treatment of IgG4-related disease, marking the first time a placebo-controlled study has shown benefit in the condition, according to a press release from Amgen.Topline results from the double-blind, randomized trial, called MITIGATE, demonstrated an 87% reduced risk for IgG4-related disease (IgG4-RD) flare in patients

USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in Antibody-Drug Conjugates (ADCs). From May 31 ...

Approximately one in five people worldwide have elevated Lp levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics...

Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1The Roche Diagnostics Tina-quant®

Swiss drug major Roche Holding AG (RHHBY) announced Wedensday that the Tina-quant lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.

More than 234,000 new cases of lung cancer are expected to be diagnosed in the US this year

Amgen and AstraZeneca have reported data from a trial that showed the effectiveness of their asthma drug Tezspire in certain patients with COPD.

The agency cleared the drug, called Imdelltra, as a second or later-line treatment for adults with advanced small-cell lung cancer.

-The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgens tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small...

U.S. Food and Drug Administration fast-tracks approval for Amgen drug shown to shrink lung tumours